Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine and Ketamine in Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years old and less than 75 years years old~* Horizontal abdominal incision~Exclusion Criteria:~* Emergency or urgent procedure~* Preexisting chronic pain (at any site) requiring treatment~* Contraindication to any study medication (ketamine or lidocaine)~* History of significant Axis I psychiatric disease (major depressive disorder, bipolar disorder, schizophrenia, etc.)~* Significant hepatic (ALT or AST \> 2 times normal) or renal (serum creatinine \> 2 mg/dl) impairment~* Seizure disorder requiring medication within past 2 years~* Planned spinal or epidural anesthesia or analgesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
- Placebo (Type: PLACEBO_COMPARATOR): A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
- Ketamine (Type: ACTIVE_COMPARATOR): Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
- ketamine + Lidocaine (Type: ACTIVE_COMPARATOR): both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).